Archives
-
D-Luciferin Workflows for Tumor BLI
2026-09-08
D-Luciferin supports sensitive firefly luciferase readouts for intracellular ATP quantification, promoter-driven reporter monitoring, and longitudinal tumor burden assessment. This practical guide connects assay setup and troubleshooting with a tumor-targeted immunotherapy framework while clearly separating established evidence from proposed imaging extensions.
-
Prochlorperazine in Melanoma Research Workflows
2026-09-07
Prochlorperazine combines dopamine D2 receptor antagonism with experimentally useful effects on melanoma phenotypes and clathrin-mediated endocytosis. This practical guide covers dose selection, assay controls, antiviral screening logic, and troubleshooting for reproducible cell-based research.
-
TCAIM, OGDH, and Mitochondrial Metabolism
2026-09-07
Wang and colleagues identify TCAIM as a mitochondrial DNAJC co-chaperone that selectively binds native OGDH and promotes its reduction through HSPA9 and LONP1. The study establishes mitochondrial proteostasis as a post-translational control point for OGDH complex activity, carbohydrate catabolism, and broader metabolic state.
-
ATP as a Translational Lens on Mitochondrial Control
2026-09-05
Adenosine Triphosphate is more than a cellular fuel or assay endpoint. This thought-leadership article connects ATP measurement and experimentation with new evidence that the mitochondrial co-chaperone TCAIM selectively reduces OGDH through HSPA9 and LONP1, offering translational researchers a framework for linking proteostasis, mitochondrial metabolism, and experimental strategy.
-
Dronedarone (Multaq) in Atrial Fibrillation Research
2026-09-04
Dronedarone (Multaq) is more than a familiar rhythm-control compound: it is a useful mechanistic probe for separating broad antiarrhythmic pharmacology from atrial-selective KCa2 channel biology. This thought-leadership guide connects evidence from automated patch-clamp research with practical assay design, exposure alignment, and translational strategy.
-
LNP Surface Charge Meets Cellular V-ATPase Activity
2026-09-04
A 2026 study proposes that lipid nanoparticle tropism is governed by a two-sided interaction between LNP surface charge and the V-ATPase activity of recipient cells. Its in vitro and in vivo experiments connect cellular endo/lysosomal state with charge-dependent delivery, suggesting that target-cell biology should be measured alongside nanoparticle properties when optimizing nucleic acid delivery.
-
HyperScribe SP6 High Yield RNA Synthesis Kit
2026-09-03
Build high-yield, sequence-specific RNA for probes, translation, RNAi, and research-stage vaccine workflows with flexible nucleotide modification. The kit also enables practical assay development around GADD34 mRNA localization and SARS-CoV-2 nucleocapsid-mediated innate immune suppression.
-
Intravesical p21 mRNA-LNP Therapy for Bladder Cancer
2026-09-03
A 2026 FASEB Journal study developed chemically modified p21 mRNA in lipid nanoparticles for localized intravesical treatment of bladder cancer. The approach restored nuclear p21 expression, suppressed tumor-cell growth, and reduced orthotopic tumor burden while limiting systemic distribution, supporting tumor suppressor replacement as a preclinical strategy.
-
QRICH1, ER Stress, and HBV-Driven HMGB1
2026-09-02
A 2025 Immunobiology study identifies QRICH1 as an important effector connecting endoplasmic reticulum stress with HMGB1 transcription, acetylation, translocation, and secretion during HBV-associated hepatic fibrosis. Its mouse, patient-specimen, histological, biochemical, and transcriptional evidence refines the mechanistic model of inflammatory liver injury and highlights testable points for future validation.
-
Praeruptorin A: From Pathways to Assay Design
2026-09-02
Praeruptorin A is an angular pyranocoumarin compound with reported activity across ferroptosis, inflammation, barrier integrity, metastasis, and cardiomyopathy research. This assay-first guide explains how to translate its multi-target profile into better controls, readouts, and preclinical decisions.
-
Azathramycin A: Research Workflows and Troubleshooting
2026-09-01
Azathramycin A supports ribosome-focused tuberculosis research, impurity profiling, and mechanism-led antibacterial assays. This practical guide combines solvent handling, cell-based workflow design, resistance study planning, and troubleshooting for more reproducible results.
-
ATP Workflows for Mitochondrial Metabolism
2026-09-01
Learn how Adenosine Triphosphate (ATP) can anchor quantitative workflows for mitochondrial energetics, OGDH regulation, and extracellular signaling. This guide connects the TCAIM–OGDH discovery to practical ATP preparation, assay design, controls, and troubleshooting without confusing ATP abundance with enzyme activity or protein stability.
-
Cucurbitacin I (JSI-124) STAT3 Assay Guide
2026-08-31
Build mechanism-led cancer workflows around Cucurbitacin I, from phospho-STAT3 validation to invasion, apoptosis, combination, and xenograft studies. The guide also shows how a human SAN-cardiac plexus assembloid study can inspire better multicellular assay design without overstating cross-domain evidence.
-
Hoechst 33258 in Tumor pH Translation
2026-08-31
Hoechst 33258 can serve as a practical nuclear readout for translational studies of tumor pH homeostasis, lactate export, drug activation, and immune remodeling. This article connects its minor-groove binding mechanism with experimental strategies for validating biomimetic microparticle therapies while clarifying what the stain can—and cannot—demonstrate.
-
YM 58483 (BTP2): SOCE Assay Logic
2026-08-30
YM 58483 (BTP2) is a pathway-level SOCE blocker for dissecting calcium-dependent immune and fibrosis biology. This article explains how to use it as a causal perturbation tool, interpret CRAC/TRP inhibition, and avoid overclaiming ORAI2 specificity.